Parkinson’s disease is a progressive neurodegenerative disorder which results in depletion of dopamine within the substantia nigra pars compacta in the central nervous system.
Featured Learning Zones
The COMT inhibition in Parkinson's Disease Learning Zone contains key information, expert opinion and interactive learning to highlight the benefit to patients of early levodopa treatment and diagnosis of the motor fluctuations which signal disease progression and prompt adjunctive treatment. Also detailing key efficacy and safety data for the approved COMT inhibitors to help inform your treatment decisions.
Parkinson’s disease primarily affects the motor system causing the classical symptoms of bradykinesia, tremor and rigidity. In addition, Parkinson’s disease results in non-motor symptoms such as depression and dementia which can worsen over time.
The exact cause of Parkinson’s disease is unknown and there are no disease-modifying treatments. However, dopaminergic pharmacotherapies designed to restore depleted dopamine in the brain are the mainstay of treatment. These include levodopa, dopamine agonists and monoamine oxidase B (MAO-B) inhibitors.
As Parkinson’s disease progresses, motor complications emerge related to long-term symptomatic treatment. This requires more frequent dosing or the addition of other therapies, such as catechol-O-methyltransferase (COMT) inhibitors.
Visit our dedicated Parkinson’s disease Learning Zone for learning resources on diagnosing motor fluctuations, treatment guidelines and the available COMT inhibitors.
Related news and insights
Kyowa Kirin Co., Ltd. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinson’s and are currently reviewing the options available, which may include re-examination.
Neurocrine Biosciences, Inc. announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily Ongentys (opicapone) capsules decreased "off" time and increased "on" time without troublesome dyskinesia as an add-on therapy to levodopa/carbidopa in patients with Parkinson's disease who experience motor fluctuations.
Sunovion Pharmaceuticals Inc. announced on 15 June 2020 hat Health Canada has approved Kynmobi (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa.